Compare BBAR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | DYN |
|---|---|---|
| Founded | 1886 | 1984 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 1997 | 2020 |
| Metric | BBAR | DYN |
|---|---|---|
| Price | $16.31 | $18.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $17.00 | ★ $37.00 |
| AVG Volume (30 Days) | 727.7K | ★ 1.9M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.32 | N/A |
| Revenue Next Year | $11.04 | N/A |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.76 | $7.01 |
| 52 Week High | $23.10 | $25.00 |
| Indicator | BBAR | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 55.04 |
| Support Level | $15.23 | $18.32 |
| Resistance Level | $17.36 | $19.65 |
| Average True Range (ATR) | 0.84 | 1.09 |
| MACD | 0.30 | 0.05 |
| Stochastic Oscillator | 81.95 | 58.97 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.